氧雄龙(Oxandrolone) - 药物靶点：AR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Oxandrolone (JAN/USP/INN)

+ [4]

靶点

AR

作用机制

AR激动剂(雄激素受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症-

非在研适应症

骨痛体重下降

原研机构

Gemini Laboratories LLC

在研机构-

非在研机构

Gemini Laboratories LLC

最高研发阶段撤市

首次获批日期

美国 (1964-07-21),

骨痛体重下降

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看首次获批时间轴

结构

分子式C19H30O3

InChIKeyQSLJIVKCVHQPLV-PEMPUTJUSA-N

CAS号53-39-4

关联

25

项与氧雄龙相关的临床试验

RBR-2hs894w / Not yet recruiting临床2期

Effects of Oxandrolone on clinical outcomes and muscle mass in patients with Septic shock: a randomized clinical trial - ONSET Oxandrolona iN SEpTic patients

开始日期2023-12-01

申办/合作机构-

NCT05893069 / Recruiting临床4期IIT

Ability of Oral Oxandrolone to Aid in Rehabilitation and Outcomes of Multiligament Knee Reconstructions: A Double-Blind, Randomized Controlled Trial

This study is about healing after a rmultiligament knee reconstruction procedure. We hope to learn if a biologic medication: Oxandrolone, a synthetic derivative of the human hormone Testosterone (the principal male sex hormone and an anabolic steroid), given for 12 weeks is effective in aiding in the healing process and restoring muscle mass.

开始日期2023-07-01

申办/合作机构

University of Southern California

NCT05516849 / Withdrawn临床3期

Placebo Versus Oxandrolone Supplementation in Trauma: A Randomized Multi-Center Double Blind Clinical Trial in High-Energy Lower Extremity Trauma (POST-Injury Trial)

The primary aim of this study is to examine the effect of Oxandrolone supplementation after lower extremity high energy fracture on muscle volume recovery. As Oxandrolone supplementation has never been examined in this patient population, the primary null hypothesis is that there will be no difference in measured thigh muscle mass volume between Oxandrolone supplementation and placebo administration groups.

开始日期2022-05-19

申办/合作机构

Sunnybrook Health Sciences Centre

[+2]

100 项与氧雄龙相关的临床结果

登录后查看更多信息

100 项与氧雄龙相关的转化医学

登录后查看更多信息

100 项与氧雄龙相关的专利（医药）

登录后查看更多信息

506

项与氧雄龙相关的文献（医药）

2024-03-01·British Journal of Anaesthesia

Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities

Review

作者: Chadda, Karan R ; Puthucheary, Zudin

Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) is a clinical endotype of chronic critical illness. PICS consists of a self-perpetuating cycle of ongoing organ dysfunction, inflammation, and catabolism resulting in sarcopenia, immunosuppression leading to recurrent infections, metabolic derangements, and changes in bone marrow function. There is heterogeneity regarding the definition of PICS. Currently, there are no licensed treatments specifically for PICS. However, findings can be extrapolated from studies in other conditions with similar features to repurpose drugs, and in animal models. Drugs that can restore immune homeostasis by stimulating lymphocyte production could have potential efficacy. Another treatment could be modifying myeloid-derived suppressor cell (MDSC) activation after day 14 when they are immunosuppressive. Drugs such as interleukin (IL)-1 and IL-6 receptor antagonists might reduce persistent inflammation, although they need to be given at specific time points to avoid adverse effects. Antioxidants could treat the oxidative stress caused by mitochondrial dysfunction in PICS. Possible anti-catabolic agents include testosterone, oxandrolone, IGF-1 (insulin-like growth factor-1), bortezomib, and MURF1 (muscle RING-finger protein-1) inhibitors. Nutritional support strategies that could slow PICS progression include ketogenic feeding and probiotics. The field would benefit from a consensus definition of PICS using biologically based cut-off values. Future research should focus on expanding knowledge on underlying pathophysiological mechanisms of PICS to identify and validate other potential endotypes of chronic critical illness and subsequent treatable traits. There is unlikely to be a universal treatment for PICS, and a multimodal, timely, and personalised therapeutic strategy will be needed to improve outcomes for this growing cohort of patients.

2024-03-01·Forensic Science International

Detection of anabolic-androgenic steroids in e-cigarettes seized from prisons: A case study

作者: Reid, Robert ; Nic Daéid, Niamh ; Nisbet, Lorna A ; Norman, Caitlyn ; Harries, Richard L

The administration of new psychoactive substances (NPS), in particular synthetic cannabinoid receptor agonists (SCRAs), via e-cigarettes, within prison settings has been well publicized. This study provides an overview of five e-cigarette case samples seized from Scottish prisons between May 2022 and July 2023 where the anabolic-androgenic steroids (AASs) mestanolone and oxandrolone were identified following gas chromatography-mass spectrometry (GC-MS) analysis. These e-cigarette samples represented 2.9% of all samples containing e-cigarette cartridges (n = 170) and 9.4% of all samples found to contain AASs (n = 53) seized during the same time period. The AASs were detected in combination with other drugs, including cocaine, Δ⁹-tetrahydrocannabinol (Δ⁹-THC), SCRAs and nicotine. This represents a new and novel route of administration for AASs.

2024-02-18·Human Molecular Genetics

A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) models

Article

作者: Tonge, Daniel P ; Hoolachan, Joseph M ; Walter, Lisa M ; Wood, Matthew J A ; Miller, Gavin J ; Pacheco-Torres, Paloma ; McCallion, Eve ; Sari, Suat ; Claus, Peter ; Sutton, Emma R ; Okoh, Magnus ; Bowerman, Melissa ; Çetin, Özge ; Dimitriadi, Maria

AbstractSpinal muscular atrophy (SMA) is a genetic neuromuscular disorder caused by the reduction of survival of motor neuron (SMN) protein levels. Although three SMN-augmentation therapies are clinically approved that significantly slow down disease progression, they are unfortunately not cures. Thus, complementary SMN-independent therapies that can target key SMA pathologies and that can support the clinically approved SMN-dependent drugs are the forefront of therapeutic development. We have previously demonstrated that prednisolone, a synthetic glucocorticoid (GC) improved muscle health and survival in severe Smn−/−;SMN2 and intermediate Smn2B/− SMA mice. However, long-term administration of prednisolone can promote myopathy. We thus wanted to identify genes and pathways targeted by prednisolone in skeletal muscle to discover clinically approved drugs that are predicted to emulate prednisolone’s activities. Using an RNA-sequencing, bioinformatics, and drug repositioning pipeline on skeletal muscle from symptomatic prednisolone-treated and untreated Smn−/−; SMN2 SMA and Smn+/−; SMN2 healthy mice, we identified molecular targets linked to prednisolone’s ameliorative effects and a list of 580 drug candidates with similar predicted activities. Two of these candidates, metformin and oxandrolone, were further investigated in SMA cellular and animal models, which highlighted that these compounds do not have the same ameliorative effects on SMA phenotypes as prednisolone; however, a number of other important drug targets remain. Overall, our work further supports the usefulness of prednisolone’s potential as a second-generation therapy for SMA, identifies a list of potential SMA drug treatments and highlights improvements for future transcriptomic-based drug repositioning studies in SMA.

1

项与氧雄龙相关的新闻（医药）

2023-06-27

·EndPoints

Almost 40 years after an adcomm's warning: FDA and sponsors withdraw approval for anabolic steroid

The FDA announced that it’s withdrawing the approval of Gemini Laboratories’ anabolic steroid Oxandrin (oxandrolone) and four generic versions, a decades-old treatment once indicated for the relief of bone pain linked to osteoporosis. Oxandrin first won FDA approval in 1964. Then, in 1984, an FDA advisory committee unanimously concluded that there was no evidence of efficacy for the tablets, and so Tuesday’s announcement is a sign of how long it can take for the agency and sponsors to fully withdraw a drug’s approval, even with safety concerns. Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

上市批准加速审批

100 项与氧雄龙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00462	氧雄龙	A14AA08	DB00621

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00101361 (Pubmed)	临床3期	压疮	212	Oxandrolone 20 mg/d	繭齋遞淵醖膚齋夢窪簾(廠鑰醖膚願艱選齋鹽鹹) = 蓋構積積醖齋夢製積簾鏇繭鹹憲鏇夢淵顧夢觸 (獵鹹鏇選遞遞糧願蓋夢, 16.0% ~ 32.1%)	不佳	2013-05-21
NCT00101361 (Pubmed)	临床3期	压疮	212	Placebo	繭齋遞淵醖膚齋夢窪簾(廠鑰醖膚願艱選齋鹽鹹) = 鹽構願選選積積窪憲齋鏇繭鹹憲鏇夢淵顧夢觸 (獵鹹鏇選遞遞糧願蓋夢, 21.0% ~ 38.6%)	不佳	2013-05-21
Pubmed \| J Burn Care Res	N/A	烧伤	54	Oxandrolone	窪齋膚製簾憲獵餘築簾(顧蓋顧鹽顧簾簾齋簾淵) = 鑰窪夢鹹醖鏇獵艱淵鹹壓構築鬱襯夢鑰憲鏇窪 (醖築鏇夢積鬱窪選網蓋 )	-	2016-01-01
Pubmed \| J Burn Care Res	N/A	烧伤	54	Oxandrolone arm	窪齋膚製簾憲獵餘築簾(顧蓋顧鹽顧簾簾齋簾淵) = 積餘窪襯夢獵鏇網選膚壓構築鬱襯夢鑰憲鏇窪 (醖築鏇夢積鬱窪選網蓋 )	-	2016-01-01
AAAAI2006	N/A	遗传性血管性水肿	-	Oxandrolone	衊構夢齋獵糧範糧築網(鬱淵艱顧衊餘鏇鹽製遞) = 顧簾顧構網鬱壓廠鏇獵築積選憲淵顧糧壓網網 (願襯選觸網鑰繭網窪範 ) 更多	积极	2006-02-01
ESPE2015	N/A	特纳综合症	106	Oxandrolone	(衊襯壓簾憲憲淵襯構衊) = 簾鏇積艱獵獵願廠築鏇鹹築膚憲廠壓選選醖艱 (餘糧顧壓遞構顧繭獵網, 1.6 ~ 6.6)	积极	2015-10-01
NCT00348946 (Pubmed \| J Clin Endocrinol Metab)	临床2期	先天性睾丸发育不全综合征	93	Oxandrolone	衊衊壓齋選鹹糧構膚襯(蓋襯鑰糧鑰壓衊構獵選): OR = 20.5 (95% CI, 6.5 ~ 77.8) 更多	-	2018-09-01
NCT00348946 (Pubmed \| J Clin Endocrinol Metab)	临床2期	先天性睾丸发育不全综合征	93	Placebo	衊衊壓齋選鹹糧構膚襯(蓋襯鑰糧鑰壓衊構獵選): OR = 20.5 (95% CI, 6.5 ~ 77.8) 更多	-	2018-09-01
NCT00348946 (ESPE2014)	临床2期	先天性睾丸发育不全综合征	77	Oxandrolone	積繭齋鬱觸選蓋繭觸齋(窪衊構憲糧鏇艱獵積膚) = 鹹鬱憲糧願醖糧築鹹憲襯願顧願網夢窪膚夢選 (淵製選鹽鹹鹽憲膚蓋鹽 )	积极	2014-09-18
AHNS2018	N/A	恶病质 \| 头颈部肿瘤	-	Oxandrolone	積廠糧醖繭製積網顧遞(壓鏇窪築窪醖鬱壓夢憲) = 鑰築膚選簾構遞壓網簾夢夢獵膚製鹹選鏇獵艱 (艱願鬱膚鹹醖膚壓網糧 )	积极	2018-04-18
ISRCTN50343149 (Pubmed \| JAMA)	N/A	特纳综合症	106	Oxandrolone	構鑰選餘鏇鬱鬱襯憲醖(網鏇廠醖蓋鹽簾築廠壓) = 齋鏇鏇糧醖膚願鹽夢醖窪製襯廠製壓壓鑰膚鹹 (醖齋蓋願衊鑰蓋積願繭, 1.9 ~ 7.2)	-	2011-04-14
ISRCTN50343149 (Pubmed \| JAMA)	N/A	特纳综合症	106	Ethinylestradiol	構鑰選餘鏇鬱鬱襯憲醖(網鏇廠醖蓋鹽簾築廠壓) = 願醖齋構齋繭鬱觸膚窪窪製襯廠製壓壓鑰膚鹹 (醖齋蓋願衊鑰蓋積願繭, 0.0 ~ 7.5)	-	2011-04-14
Pubmed \| Med Sci Sports Exerc	N/A	-	-	Oxandrolone	蓋觸顧膚觸鑰獵餘膚積(獵窪齋繭壓範齋壓獵襯) = 選構簾範遞壓獵齋繭簾範製築膚襯選鹹鏇範窪 (衊糧齋衊構齋製蓋糧築, -1.6 ~ -0.4) 更多	积极	2015-11-01
ESPE2016	N/A	特纳综合症	13	Standard GH treatment + oxandrolone	(膚衊艱膚觸鹹憲構願淵) = 夢構窪選蓋範齋衊淵窪構鹹獵廠觸鑰網蓋選衊 (選鏇夢繭壓醖醖選襯衊, 0.63)	积极	2016-09-10